Point Biopharma, Isotopia sign clinical agreement for isotope

By AuntMinnie.com staff writers

July 23, 2021 -- Point Biopharma Global and Isotopia Molecular Imaging announced the companies have signed a clinical supply agreement for the medical radioisotope lutetium-177, a therapeutic isotope used in Point's pipeline of radiopharmaceutical assets.

Company leaders touted lutetium-177's 6.6-day half-life, saying it is short enough for use with a variety of radiopharmaceuticals and long enough to minimize decay loss during preparation and shipping. They also said the isotope damages tumors when bound to disease-specific targeting therapeutics.

The isotope will be used at Point's Indianapolis facility in the manufacturing of its therapeutic radioligand therapies.

Copyright © 2021 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking